Morphic Therapeutic News Today

The significant growth in the ambulatory surgical centers market can be credited to several factors highlighting the rising need for multispecialty outpatient surgical facilities. A primary

/PRNewswire/ -- DelveInsights Infection Prevention and Control Market Insights report provides the current and forecast market analysis, individual leading...

The surge in the infection prevention and control demand market is due to factors such as the rising occurrence of chronic diseases, escalating rates of surgical procedures necessitating stringent

Vir Biotechnology, Inc. today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors at its upcoming annual meeting of stockholders on May 29, 2024...

BioPharma

DeepMirror, a University of Cambridge spin-out, introduces its Early Access Programme for intuitive design software dedicated to discovering innovative therapeutic drugs. Click to read more...

/PRNewswire/ -- DelveInsights Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices,...

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen...

Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United 

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.